NASDAQ:ALNAAllena Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allena Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.71 -0.09 (-5.00 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$1.69Now: $1.71▼$1.8050-Day Range$0.96MA: $1.63▼$1.9752-Week Range$0.53Now: $1.71▼$6.30Volume170,100 shsAverage Volume292,693 shsMarket Capitalization$42.31 millionP/E RatioN/ADividend YieldN/ABeta2.93 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAllena Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Allena Pharmaceuticals has a potential upside of 601.8% from its current price of $1.71.Amount of Analyst CoverageAllena Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAllena Pharmaceuticals has received 217 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllena Pharmaceuticals has received 209 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllena Pharmaceuticals has received 50.94% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllena Pharmaceuticals does not currently pay a dividend.Dividend GrowthAllena Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allena Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders38.60% of the stock of Allena Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.65% of the stock of Allena Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allena Pharmaceuticals are expected to grow in the coming year, from ($0.97) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allena Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allena Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllena Pharmaceuticals has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA Previous Symbol CUSIPN/A CIK1624658 Webwww.allenapharma.com Phone617-467-4577Debt Debt-to-Equity Ratio0.47 Current Ratio2.84 Quick Ratio2.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book3.98Profitability EPS (Most Recent Fiscal Year)($2.10) Net Income$-47,340,000.00 Net MarginsN/A Return on Equity-189.16% Return on Assets-111.34%Miscellaneous Employees34 Outstanding Shares24,742,000Market Cap$42.31 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:ALNA Rates by TradingView Receive ALNA News and Ratings via Email Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter. Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions How has Allena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALNA stock has increased by 35.7% and is now trading at $1.71. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Allena Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allena Pharmaceuticals. When is Allena Pharmaceuticals' next earnings date? Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Allena Pharmaceuticals. How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals Inc (NASDAQ:ALNA) issued its earnings results on Wednesday, May, 13th. The company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.14. View Allena Pharmaceuticals' earnings history. What price target have analysts set for ALNA? 4 brokers have issued 1 year price objectives for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $26.00. On average, they expect Allena Pharmaceuticals' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 601.8% from the stock's current price. View analysts' price targets for Allena Pharmaceuticals. Has Allena Pharmaceuticals been receiving favorable news coverage? News headlines about ALNA stock have trended very negative recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAllena Pharmaceuticals. Are investors shorting Allena Pharmaceuticals? Allena Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 321,400 shares, an increase of 11.1% from the April 30th total of 289,200 shares. Based on an average daily trading volume, of 325,800 shares, the days-to-cover ratio is currently 1.0 days. Currently, 2.3% of the shares of the stock are short sold. View Allena Pharmaceuticals' Current Options Chain. Who are some of Allena Pharmaceuticals' key competitors? Some companies that are related to Allena Pharmaceuticals include Cabaletta Bio (CABA), Dyadic International (DYAI), LogicBio Therapeutics (LOGC), Cidara Therapeutics (CDTX), Solid Biosciences (SLDB), Erytech Pharma (ERYP), X4 Pharmaceuticals (XFOR), Gamida Cell (GMDA), Surface Oncology (SURF), Applied Genetic Technologies (AGTC), BIONDVAX PHARMA/S (BVXV), Champions Oncology (CSBR), Windtree Therapeutics (WINT), Neon Therapeutics (NTGN) and Genocea Biosciences (GNCA). View all competitors. What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Exelixis (EXEL), Matinas BioPharma (MTNB), Opko Health (OPK), Amarin (AMRN) and Pieris Pharmaceuticals (PIRS). Who are Allena Pharmaceuticals' key executives? Allena Pharmaceuticals' management team includes the following people: Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 67, Pay $427.95k)Dr. Louis Brenner, Pres, CEO & Director (Age 50, Pay $507.28k)Mr. Edward J. Wholihan, Chief Financial Officer (Age 60, Pay $387.03k)Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 55)Mr. Hugh Wight, Sr. VP of Technical Operations When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Allena Pharmaceuticals' stock symbol? Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA." Who are Allena Pharmaceuticals' major shareholders? Allena Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (5.07%), Sphera Funds Management LTD. (2.70%) and BlackRock Inc. (0.49%). View institutional ownership trends for Allena Pharmaceuticals. Which major investors are selling Allena Pharmaceuticals stock? ALNA stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., and BlackRock Inc.. View insider buying and selling activity for Allena Pharmaceuticals. Which major investors are buying Allena Pharmaceuticals stock? ALNA stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Allena Pharmaceuticals. How do I buy shares of Allena Pharmaceuticals? Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allena Pharmaceuticals' stock price today? One share of ALNA stock can currently be purchased for approximately $1.71. How big of a company is Allena Pharmaceuticals? Allena Pharmaceuticals has a market capitalization of $42.31 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe. What is Allena Pharmaceuticals' official website? The official website for Allena Pharmaceuticals is www.allenapharma.com. How can I contact Allena Pharmaceuticals? Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577. This page was last updated on 5/28/2020 by MarketBeat.com Staff
